188 related articles for article (PubMed ID: 23863814)
1. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Sosenko JM; Skyler JS; Beam CA; Krischer JP; Greenbaum CJ; Mahon J; Rafkin LE; Matheson D; Herold KC; Palmer JP;
Diabetes; 2013 Dec; 62(12):4179-83. PubMed ID: 23863814
[TBL] [Abstract][Full Text] [Related]
2. Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced β-cell autoimmunity.
Siljander HT; Hermann R; Hekkala A; Lähde J; Tanner L; Keskinen P; Ilonen J; Simell O; Veijola R; Knip M
Eur J Endocrinol; 2013 Oct; 169(4):479-85. PubMed ID: 23904276
[TBL] [Abstract][Full Text] [Related]
3. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Sosenko JM; Palmer JP; Rafkin LE; Krischer JP; Cuthbertson D; Greenbaum CJ; Eisenbarth G; Skyler JS;
Diabetes Care; 2010 Mar; 33(3):620-5. PubMed ID: 20032282
[TBL] [Abstract][Full Text] [Related]
4. Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.
Baidal DA; Warnock M; Xu P; Geyer S; Marks JB; Moran A; Sosenko J; Evans-Molina C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3273-e3280. PubMed ID: 35524749
[TBL] [Abstract][Full Text] [Related]
5. Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies.
Koskinen MK; Lempainen J; Löyttyniemi E; Helminen O; Hekkala A; Härkönen T; Kiviniemi M; Simell O; Knip M; Ilonen J; Toppari J; Veijola R
J Clin Endocrinol Metab; 2018 Aug; 103(8):2870-2878. PubMed ID: 29300921
[TBL] [Abstract][Full Text] [Related]
6. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.
Böhmer KP; Kolb H; Kuglin B; Zielasek J; Hübinger A; Lampeter EF; Weber B; Kolb-Bachofen V; Jastram HU; Bertrams J
Diabetes Care; 1994 Feb; 17(2):138-41. PubMed ID: 8137684
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and fasting plasma glucose in first degree relatives of patients with type 1 diabetes.
Siewko K; Popławska-Kita A; Telejko B; Maciulewski R; Zielińska A; Nikołajuk A; Górska M; Szelachowska M
J Diabetes Complications; 2013; 27(6):593-6. PubMed ID: 23890682
[TBL] [Abstract][Full Text] [Related]
8. Reduced β-cell function in early preclinical type 1 diabetes.
Koskinen MK; Helminen O; Matomäki J; Aspholm S; Mykkänen J; Mäkinen M; Simell V; Vähä-Mäkilä M; Simell T; Ilonen J; Knip M; Veijola R; Toppari J; Simell O
Eur J Endocrinol; 2016 Mar; 174(3):251-9. PubMed ID: 26620391
[TBL] [Abstract][Full Text] [Related]
9. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
10. β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.
Evans-Molina C; Sims EK; DiMeglio LA; Ismail HM; Steck AK; Palmer JP; Krischer JP; Geyer S; Xu P; Sosenko JM;
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089716
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance is a risk factor for progression to type 1 diabetes.
Fourlanos S; Narendran P; Byrnes GB; Colman PG; Harrison LC
Diabetologia; 2004 Oct; 47(10):1661-7. PubMed ID: 15480539
[TBL] [Abstract][Full Text] [Related]
12. Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention.
Elding Larsson H; Larsson C; Lernmark Å;
Acta Diabetol; 2015 Jun; 52(3):473-81. PubMed ID: 25381193
[TBL] [Abstract][Full Text] [Related]
13. Role of insulin resistance in predicting progression to type 1 diabetes.
Xu P; Cuthbertson D; Greenbaum C; Palmer JP; Krischer JP;
Diabetes Care; 2007 Sep; 30(9):2314-20. PubMed ID: 17536068
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention studies.
Mahon JL; Beam CA; Marcovina SM; Boulware DC; Palmer JP; Winter WE; Skyler JS; Krischer JP;
Clin Chim Acta; 2011 Nov; 412(23-24):2128-31. PubMed ID: 21843518
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Pattern of First-Phase Insulin Response Is Associated With Genetic Variants Outside the Class II HLA Region in Children With Multiple Autoantibodies.
Koskinen MK; Mikk ML; Laine AP; Lempainen J; Löyttyniemi E; Vähäsalo P; Hekkala A; Härkönen T; Kiviniemi M; Simell O; Knip M; Veijola R; Ilonen J; Toppari J
Diabetes; 2020 Jan; 69(1):12-19. PubMed ID: 31591105
[TBL] [Abstract][Full Text] [Related]
16. Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study.
Andersson C; Carlsson A; Cilio C; Cedervall E; Ivarsson SA; Jonsdottir B; Jönsson B; Larsson K; Neiderud J; Lernmark A; Elding Larsson H;
Pediatr Diabetes; 2013 Aug; 14(5):341-9. PubMed ID: 23469940
[TBL] [Abstract][Full Text] [Related]
17. Staging of preclinical type 1 diabetes in siblings of affected children. Childhood Diabetes in Finland Study Group.
Mrena S; Savola K; Kulmala P; Akerblom HK; Knip M
Pediatrics; 1999 Oct; 104(4 Pt 1):925-30. PubMed ID: 10506236
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of glucose metabolism in preclinical type 1 diabetes.
Veijola R; Koskinen M; Helminen O; Hekkala A
Pediatr Diabetes; 2016 Jul; 17 Suppl 22():25-30. PubMed ID: 27411433
[TBL] [Abstract][Full Text] [Related]
19. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics.
Olmos PR; Hodgson MI; Maiz A; Manrique M; De Valdés MD; Foncea R; Acosta AM; Emmerich MV; Velasco S; Muñiz OP; Oyarzún CA; Claro JC; Bastías MJ; Toro LA
Diabetes Res Clin Pract; 2006 Mar; 71(3):320-33. PubMed ID: 16233932
[TBL] [Abstract][Full Text] [Related]
20. The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.
Ismail HM; Cleves MA; Xu P; Libman IM; Becker DJ; Marks JB; Skyler JS; Palmer JP; Sosenko JM;
Diabetes Care; 2020 Nov; 43(11):2668-2674. PubMed ID: 32900788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
